Outcome of Board Meeting held today i.e. Wednesday, 26th November, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Dipna Pharmachem Limited approved the unaudited financial results for the half year ended September 30, 2025 along with the Limited Review Report. Total income from operations stood at Rs. 7,354.12 lakhs in H1 FY26, down about 20% from Rs. 9,062.38 lakhs in H1 FY25, mainly due to lower purchases of stock-in-trade. Despite the revenue decline, net profit jumped sharply to Rs. 141.10 lakhs (from Rs. 33.67 lakhs), and basic EPS rose to Rs. 0.59 (from Rs. 0.14). The company also confirmed there are no deviations in the utilization of proceeds from the Rights Issue (Rs. 11.84 crore raised in March 2024) and the Preferential Issue of convertible warrants (Rs. 18.93 crore received as 25% consideration in September 2025). The auditor's review report by Devadiya & Associates was clean, with no qualifications.
Lower top-line is a concern, but strong profit growth and expanded margins indicate better cost discipline or a favorable product mix. The fresh capital infusion via convertible warrants strengthens the balance sheet (other equity rose to Rs. 5,808 lakhs from Rs. 3,049 lakhs), though the persistent negative operating cash flow of Rs. -1,771 lakhs remains a watch-point for shareholders.